During the past decade, Bluegrass Internal Medicine conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Bluegrass Internal Medicine" #1 collaborator was "Sucampo Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Bluegrass Internal Medicine" are "Fibromyalgia" (1 trials) and "Opioid-induced Bowel Dysfunction" (1 trials). Many other conditions were trialed in "Bluegrass Internal Medicine" in a lesser frequency.

Most popular intervention types in "Bluegrass Internal Medicine" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Lubiprostone" (1 trials), "Placebo" (1 trials), "Xyrem®" (1 trials) and "placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Bluegrass Internal Medicine" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Bluegrass Internal Medicine". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Bluegrass Internal Medicine, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Bluegrass Internal Medicine, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".